Medication info
Teramet XR Sustained Release Tablet 50/500 milligrams

Teramet XR Sustained Release Tablet 50/500 milligrams

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Bright blue, oval-shaped, bilaterally convex sustained-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202012 · Approved 2022.05.13 · Insurance code 698504770

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually. To preserve the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start this medicine at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is administered to patients with type 2 diabetes, helping to improve blood sugar control through the combined action of sitagliptin and metformin. When taken alongside dietary and exercise regimens, it effectively aids in managing blood sugar. Thus, this medication is used to improve blood sugar control in type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually. To preserve the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start this medicine at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin components and is used in diabetes treatment. Firstly, although rare, sitagliptin can cause serious allergic reactions; therefore, if symptoms such as itching, rash, or breathing difficulties occur, the medication should be discontinued immediately, and a doctor consulted. Additionally, acute pancreatitis may occur, so if abdominal pain, nausea, or vomiting symptoms develop, notify healthcare professionals promptly. Metformin can rarely cause a serious side effect known as lactic acidosis; thus, if sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occurs, discontinue use immediately and visit a hospital. Patients with reduced kidney function or poor liver function should not take this medication and should undergo regular kidney function tests. This drug should not be administered to patients with specific conditions such as moderate to severe kidney impairment, acute heart failure, severe infections, dehydration, or acute myocardial infarction. Pregnant or breastfeeding women should also avoid using this medication. As there is a risk of hypoglycemia, caution is needed if meal patterns are irregular or intense physical activity is performed, and when used in combination with other blood glucose-lowering agents, dose adjustments may be necessary after consulting with healthcare professionals. During treatment, side effects such as diarrhea, headaches, and upper respiratory tract infections may occur; rarely, joint pain or skin disorders can arise, so if unusual symptoms persist, inform healthcare professionals. Moreover, excessive alcohol consumption should be avoided while taking this medication, and it should be temporarily discontinued before and after surgery. Finally, safety and efficacy have not been established for children (under 18 years) or children under 10 years, so this medication should not be used. Regular blood tests and kidney function tests are needed while taking this medication, and if any unusual symptoms appear, consult with healthcare professionals immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 20 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and debilitating arthralgia
  • vesicular dermatosis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemic episode
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best to maintain the storage temperature at room temperature between 1°C and 30°C. Proper storage will help preserve the medication's efficacy and safety.

Appearance and packaging

Appearance

Bright blue, oval-shaped, bilaterally convex sustained-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.